Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas

Pier Luigi Zinzani, Vijayveer Bonthapally, Dirk Huebner, Richard Lutes, Andy Chi, Stefano Pileri

Research output: Contribution to journalArticle

Abstract

Primary cutaneous T-cell lymphomas (CTCLs), such as mycosis fungoides and Sézary syndrome, are a rare group of non-Hodgkin lymphomas, usually treated using a multimodal approach. Unfortunately, many patients go on to develop relapsed/refractory disease. Systemic treatment for relapsed/refractory CTCL has historically relied on chemotherapies and interferons, and while active, responses are often short-lived. Three drugs are now approved in the US to treat relapsed/refractory CTCL including the oral retinoid, bexarotene, and histone deacetylase inhibitors, romidepsin and vorinostat. Although response rates are typically

Original languageEnglish
Pages (from-to)228-240
Number of pages13
JournalCritical Reviews in Oncology/Hematology
Volume99
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Cutaneous T-Cell Lymphoma
T-Cell Lymphoma
Mycosis Fungoides
Histone Deacetylase Inhibitors
Retinoids
Non-Hodgkin's Lymphoma
Interferons
Therapeutics
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Bexarotene
  • Brentuximab vedotin
  • Cutaneous T-cell lymphoma
  • Mycosis fungoides
  • Romidepsin
  • Sézary syndrome
  • Vorinostat

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas : Cutaneous T-cell lymphomas. / Zinzani, Pier Luigi; Bonthapally, Vijayveer; Huebner, Dirk; Lutes, Richard; Chi, Andy; Pileri, Stefano.

In: Critical Reviews in Oncology/Hematology, Vol. 99, 01.03.2016, p. 228-240.

Research output: Contribution to journalArticle

Zinzani, Pier Luigi ; Bonthapally, Vijayveer ; Huebner, Dirk ; Lutes, Richard ; Chi, Andy ; Pileri, Stefano. / Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas : Cutaneous T-cell lymphomas. In: Critical Reviews in Oncology/Hematology. 2016 ; Vol. 99. pp. 228-240.
@article{7330db03692a498dac3a2b6614f2a2a0,
title = "Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas",
abstract = "Primary cutaneous T-cell lymphomas (CTCLs), such as mycosis fungoides and S{\'e}zary syndrome, are a rare group of non-Hodgkin lymphomas, usually treated using a multimodal approach. Unfortunately, many patients go on to develop relapsed/refractory disease. Systemic treatment for relapsed/refractory CTCL has historically relied on chemotherapies and interferons, and while active, responses are often short-lived. Three drugs are now approved in the US to treat relapsed/refractory CTCL including the oral retinoid, bexarotene, and histone deacetylase inhibitors, romidepsin and vorinostat. Although response rates are typically",
keywords = "Bexarotene, Brentuximab vedotin, Cutaneous T-cell lymphoma, Mycosis fungoides, Romidepsin, S{\'e}zary syndrome, Vorinostat",
author = "Zinzani, {Pier Luigi} and Vijayveer Bonthapally and Dirk Huebner and Richard Lutes and Andy Chi and Stefano Pileri",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.critrevonc.2015.12.018",
language = "English",
volume = "99",
pages = "228--240",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas

T2 - Cutaneous T-cell lymphomas

AU - Zinzani, Pier Luigi

AU - Bonthapally, Vijayveer

AU - Huebner, Dirk

AU - Lutes, Richard

AU - Chi, Andy

AU - Pileri, Stefano

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Primary cutaneous T-cell lymphomas (CTCLs), such as mycosis fungoides and Sézary syndrome, are a rare group of non-Hodgkin lymphomas, usually treated using a multimodal approach. Unfortunately, many patients go on to develop relapsed/refractory disease. Systemic treatment for relapsed/refractory CTCL has historically relied on chemotherapies and interferons, and while active, responses are often short-lived. Three drugs are now approved in the US to treat relapsed/refractory CTCL including the oral retinoid, bexarotene, and histone deacetylase inhibitors, romidepsin and vorinostat. Although response rates are typically

AB - Primary cutaneous T-cell lymphomas (CTCLs), such as mycosis fungoides and Sézary syndrome, are a rare group of non-Hodgkin lymphomas, usually treated using a multimodal approach. Unfortunately, many patients go on to develop relapsed/refractory disease. Systemic treatment for relapsed/refractory CTCL has historically relied on chemotherapies and interferons, and while active, responses are often short-lived. Three drugs are now approved in the US to treat relapsed/refractory CTCL including the oral retinoid, bexarotene, and histone deacetylase inhibitors, romidepsin and vorinostat. Although response rates are typically

KW - Bexarotene

KW - Brentuximab vedotin

KW - Cutaneous T-cell lymphoma

KW - Mycosis fungoides

KW - Romidepsin

KW - Sézary syndrome

KW - Vorinostat

UR - http://www.scopus.com/inward/record.url?scp=84959473991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959473991&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.12.018

DO - 10.1016/j.critrevonc.2015.12.018

M3 - Article

AN - SCOPUS:84959473991

VL - 99

SP - 228

EP - 240

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -